Exelixis (EXEL) Tops Q2 EPS by 11c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts EXEL Hot Sheet
Price: $72.75 --0%
Financial Fact:
Total operating expenses: 61.39M
Today's EPS Names:
KEEL, SENEA, XFOR, More
Financial Fact:
Total operating expenses: 61.39M
Today's EPS Names:
KEEL, SENEA, XFOR, More
Join SI Premium – FREE
Exelixis (NASDAQ: EXEL) reported Q2 EPS of $0.75, $0.11 better than the analyst estimate of $0.64. Revenue for the quarter came in at $568.3 million versus the consensus estimate of $578.46 million.
GUIDANCE:
Exelixis sees FY2025 revenue of $2.25-2.35 billion, versus the consensus of $2.341 billion.
For earnings history and earnings-related data on Exelixis (EXEL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ANI Pharma (ANIP) Tops Q3 EPS by 52c ; Offers Guidance
- Climb Bio, Inc. (CLYM) Tops Q3 EPS by 2c
- Entrada Therapeutics, Inc. (TRDA) Tops Q3 EPS by 7c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
